Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
CME Credit Available: Maximum of 11.0 AMA PRA Category 1 Credits™
Release Date: January 12, 2010
Expiration Date: January 11, 2011
The 12th Annual Clinical Conference for the Ryan White (RW) HIV/AIDS Program, Part A, B, C, or D was held October 15 to 17, 2009, at the Hyatt Regency in Dallas, Texas. The Clinical Conference was designed to provide RW practitioners with the most relevant and up-to-date information in the field of HIV/AIDS medical care. You may view and download a copy of the Clinical Conference syllabus and key slides at www.iasusa.org/rwprogram2009.
The Clinical Conference was supported by and planned in collaboration with staff from the HIV/AIDS Bureau (HAB), Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services, in alliance with the Southeast AIDS Training and Education Center (SEATEC) and the Texas/Oklahoma AIDS Education and Training Center. This state-of-the-art Continuing Medical Education program is sponsored by the International AIDS Society–USA (IAS–USA) under the HRSA contract number HHSH250200900010c.
The Webcast activity consists of audio and visual recording of 13 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view a particular presentation, the learner should click on the presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he or she chooses. The learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of the Clinical Update, participants will be able to do the following:
- Design antiretroviral strategies that consider new data on:
- Initial therapy
- Interpreting resistance test results
- Managing antiretroviral regimen failure
- Describe the current state of the H1N1 virus epidemic
- Describe the incidence and management of non-AIDS-defining malignancies in HIV
- Consider current data on investigational treatments for hepatitis C virus infection, as they may impact HCV treatment in the future
- Describe the drivers of the HIV epidemic in women
- Formulate appropriate management strategies for the adolescent HIV-infected population
- Explain the key clinical issues associated with endocrine, metabolic, renal, and cardiovascular complications in HIV disease
- Formulate medical intervention plans for patients with addictions
- Diagnose mood disorders that are common in HIV disease
CME Credit
CME Accreditation Statement
This Clinical Conference Webcast is sponsored by the International AIDS Society–USA. The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
Credit Designation Statement
The International AIDS Society–USA designates this educational activity for a maximum of 11.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Intended Audience for CME Credit
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant for physicians, physician assistants, nurse practitioners, and other direct clinical care providers who are actively involved in HIV patient care in Ryan White funded programs.
Course Faculty
Co-Chairs and Planning Committee
Laura N. Armas-Kolostroubis, MD
Co-Chair Clinical Conference
Clinical Director
Texas/Oklahoma AIDS Education and Training Center
Parkland Health and Hospital System
Dallas, Texas
Laura W. Cheever, MD, ScM
Co-Chair Clinical Conference
Deputy Associate Administrator
Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Donna M. Jacobsen
Member, Board of Directors
Executive Director/President
International AIDS Society–USA
San Francisco, California
Michael S. Saag, MD
Co-Chair Clinical Conference
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Director, Division of Infectious Diseases and
The William C. Gorgas Center for Geographic Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Faculty
Adaora A. Adimora, MD, MPH
Professor of Medicine
Adjunct Professor of Epidemiology
Division of Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Laura N. Armas-Kolostroubis, MD
Clinical Director
Texas/Oklahoma AIDS Education and
Training Center
Parkland Health and Hospital System
Dallas, Texas
Todd T. Brown, MD, PhD
Assistant Professor of Medicine
The Johns Hopkins University
Division of Endocrinology and Metabolism
Baltimore, Maryland
R. Douglas Bruce, MD, MA, MSc
Assistant Professor of Medicine
Yale University School of Medicine
New Haven, Connecticut
Laura W. Cheever, MD, ScM
Deputy Associate Administrator
Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland
Kathleen A. Clanon, MD, FACP
Medical Director
Alameda County Medical Center-HIV Services
Center for Health Training
Oakland, California
Joel E. Gallant, MD, MPH
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine and Epidemiology
Associate Director of Johns Hopkins AIDS Service
Johns Hopkins University School of Medicine
Division of Infectious Diseases
Baltimore, Maryland
Roy M. Gulick, MD, MPH
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Chief of the Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Jaime Martinez, MD
Associate Professor of Pediatrics
University of Illinois
Stroger Hospital of Cook County/CORE Center
Division of Adolescent Medicine
Chicago, Illinois
Michael R. Noss, DO
Psychiatrist
Behavioral Health and Social Services
Community Oriented Primary-Care Clinic
Dallas, Texas
Michael S. Saag, MD
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Director, Division of Infectious Diseases and
The William C. Gorgas Center for
Geographic Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Robert T. Schooley, MD
Professor of Medicine
Head, Division of Infectious Disease
University of California San Diego
San Diego, California
Susan Swindells, MBBS
Terry K. Watanabe Professor
Medical Director of HIV Clinic
University of Nebraska Medical Center
Omaha, Nebraska
Paul A. Volberding, MD
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Marvin Sleisenger Professor of Medicine
Vice-Chair, Department of Medicine
University of California San Francisco
Chief of Medical Service
San Francisco Veterans Affairs Medical Center
San Francisco, California
Christina M. Wyatt, MD
Assistant Professor
Mount Sinai School of Medicine
Department of Medicine
Division of Nephrology
New York, New York
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on advisory boards for GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc, and chaired data and safety monitoring boards for Johnson & Johnson Research, Ltd, (Australia) and Achillion Pharmaceuticals, Inc. (Updated 02/12/09)
Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California, Los Angeles from Merck & Co, Inc, Schering-Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. She has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, and has served on data and safety monitoring boards for Achillion Pharmaceuticals, Inc, and Koronis Pharmaceuticals. (Updated 10/09/09)
Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from the National Institutes of Health, the US Centers for Disease Control and Prevention, Merck & Co, Inc, and Sanofi Pasteur. He served as a consultant to, or received honoraria from, Bristol-Myers Squibb, Merck & Co, Inc, and Janssen-Cilag. (Updated 10/02/09)
Joel E. Gallant, MD, MPH
Dr Gallant has served as a paid lecturer for Monogram Biosciences and has been a consultant to Abbott Laboratories, GlaxoSmithKline, Japan Tobacco, Merck Serono, and Pfizer, Inc. He has been a member of the data and safety monitoring boards for Koronis and VIRxSYS, served on an endpoint adjudication committee for Gilead Sciences, and been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Serono, Pfizer, Inc, and RAPID Pharmaceuticals AG. Dr Gallant has been the recipient of research grants or contracts from Roche Laboratories. (Updated 06/25/09)
Roy M. Gulick, MD, MPH
Dr Gulick has received research support from Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tibotec, and served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Virostatics. He also serves as Chair of a data and safety monitoring board for Koronis Pharmaceuticals. (Updated 10/06/09)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 10/08/09)
Douglas D. Richman, MD
Dr Richman has been a consultant to Anadys Pharmaceuticals, Inc, Biota, Bristol-Myers Squibb, Chimerx, Gen-Probe, Inc, Gilead Sciences, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, Myriad Genetics, Inc, Pfizer Inc, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. He has been a stock options holder of Chimerx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated: 10/09/09)
Michael S. Saag, MD
Dr Saag has received grants and research support from Achillion Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, and Tibotec Therapeutics. He has served as a consultant to Ardea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 10/01/09)
Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Chimerix, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, Koronis Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, TaiMed Biologics, Tibotec Therapeutics, and Vertex Pharmaceuticals. He had stock options for Achillion Pharmaceuticals, Inc, and Monogram Biosciences, Inc. (Updated 10/05/09)
Paul A. Volberding, MD
Dr Volberding has been a member of the data and safety monitoring boards Merck & Co, Inc and TaiMed Biologics and on an endpoint adjudication committee for Schering-Plough Corporation. He has provided paid legal consultation and expert testimony for commercial firms. Dr Volberding has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Inc, and Tobira Therapeutics and he has been the recipient of service grants or contracts for GlaxoSmithKline Italy. (Updated 10/08/09)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Adimora has no relevant financial affiliations to disclose. (Updated 09/06/09)
Dr Armas-Kolostroubis has no relevant financial affiliations to disclose. (Updated 10/05/09)
Dr Brown has received grants and research support from GlaxoSmithKline and Merck & Co, Inc. He has served as a consultant to Merck & Co, Inc and Serono (EMD Serono). (Updated 09/21/09)
Dr Bruce has received grants and research support from Abbott Laboratories, Merck & Co, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, and Reckitt Benckiser Pharmaceuticals, Inc. (Updated 10/05/09)
Dr Cheever has no relevant financial affiliations to disclose. (Updated 10/05/09)
Dr Clanon has no relevant financial affiliations to disclose. (Updated 09/11/09)
Dr Gallant has served as a paid lecturer for Monogram Biosciences and has been a consultant to Abbott Laboratories, GlaxoSmithKline, Japan Tobacco, Merck Serono, and Pfizer, Inc. He has been a member of the data and safety monitoring boards for Koronis and VIRxSYS, served on an endpoint adjudication committee for Gilead Sciences, and been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Serono, Pfizer, Inc, and RAPID Pharmaceuticals AG. Dr Gallant has been the recipient of research grants or contracts from Roche Laboratories. (Updated 06/25/09)
Dr Gulick has received research support from Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tibotec, and served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Virostatics. He also serves as Chair of a data and safety monitoring board for Koronis Pharmaceuticals. (Updated 10/06/09)
Dr Martinez has no relevant financial affiliations to disclose. (Updated 09/11/09)
Dr Noss has no relevant financial affiliations to disclose. (Updated 09/09/09)
Dr Saag has received grants and research support from Achillion Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, and Tibotec Therapeutics. He has served as a consultant to Ardea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 10/01/09)
Dr Schooley served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Chimerix, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, Koronis Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, TaiMed Biologics, Tibotec Therapeutics, and Vertex Pharmaceuticals. He had stock options for Achillion Pharmaceuticals, Inc, and Monogram Biosciences, Inc. (Updated 10/05/09)
Dr Swindells has served as a consultant to Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics, or as a contracted researcher for Bavarian Nordic, Norvatis Pharmaceuticals Corp, and Pfizer Inc. (Updated 10/01/2009)
Dr Volberding has been a member of the data and safety monitoring boards Merck & Co, Inc, and TaiMed Biologics and on an endpoint adjudication committee for Schering-Plough Corporation. He has provided paid legal consultation and expert testimony for commercial firms. He has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Inc, and Tobira Therapeutics and has been the recipient of service grants or contracts for GlaxoSmithKline Italy. (Updated 10/08/09)
Dr Wyatt has served as a contracted researcher for Gilead Sciences, Inc. (Updated 10/05/09)
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose (see above).
Program Development Committee
Ms Weyer was on the speakers’ bureaus of Boehringer Ingelheim and Bristol-Myers Squibb. (Updated 10/02/2009).
Dr Carmichael was a paid lecturer for GlaxoSmithKline (resigned November 2008). (Updated 06/16/09)
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, the AIDS Education and Training Centers National Resource Center, and the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org
